User profiles for Matthew P Kosloski

Matthew P. Kosloski

Regeneron
Verified email at regeneron.com
Cited by 2482

[HTML][HTML] Dupilumab in adults and adolescents with eosinophilic esophagitis

…, S Aceves, X Sun, MP Kosloski… - … England Journal of …, 2022 - Mass Medical Soc
Background Dupilumab, a fully human monoclonal antibody, blocks interleukin-4 and
interleukin-13 signaling, which have key roles in eosinophilic esophagitis. Methods We conducted …

Delivery of therapeutic proteins

DS Pisal, MP Kosloski, SV Balu-Iyer - Journal of pharmaceutical sciences, 2010 - Elsevier
The safety and efficacy of protein therapeutics are limited by three interrelated pharmaceutical
issues, in vitro and in vivo instability, immunogenicity and shorter half-lives. Novel drug …

Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial

…, Y Sun, E Laws, B Akinlade, M Dillon, MP Kosloski… - The Lancet, 2022 - thelancet.com
Background Current systemic treatments for children younger than 6 years with moderate-to-severe
atopic dermatitis that is uncontrolled with topical therapies might have suboptimal …

A phase II trial of lutikizumab, an anti–interleukin‐1α/β dual variable domain immunoglobulin, in knee osteoarthritis patients with synovitis

…, GS Kaeley, W Liu, MP Kosloski… - Arthritis & …, 2019 - Wiley Online Library
Objective To assess the efficacy and safety of the anti–interleukin‐1α/β (anti– IL ‐1α/β) dual
variable domain immunoglobulin lutikizumab ( ABT ‐981) in patients with knee osteoarthritis …

Efficacy and safety of glecaprevir/pibrentasvir in patients coinfected with hepatitis C virus and human immunodeficiency virus type 1: the EXPEDITION-2 study

…, S Samanta, TI Ng, A Gulati, MP Kosloski… - Clinical Infectious …, 2018 - academic.oup.com
Background Once-daily glecaprevir coformulated with pibrentasvir (glecaprevir/pibrentasvir)
demonstrated high rates of sustained virologic response 12 weeks after treatment (SVR12) …

[HTML][HTML] Long-term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis: results through week 52 from a phase III open-label …

…, W Soong, X Sun, Z Chen, MP Kosloski… - American journal of …, 2022 - Springer
Background For adolescent patients (aged ≥ 12 to < 18 years) with uncontrolled moderate-to-severe
atopic dermatitis (AD), 16 weeks of treatment with dupilumab resulted in …

Role of glycosylation in conformational stability, activity, macromolecular interaction and immunogenicity of recombinant human factor VIII

MP Kosloski, RD Miclea, SV Balu-Iyer - The AAPS journal, 2009 - Springer
Factor VIII (FVIII) is a multi-domain glycoprotein that is an essential cofactor in the blood
coagulation cascade. Its deficiency or dysfunction causes hemophilia A, a bleeding disorder. …

Pharmacokinetics and pharmacodynamics of itepekimab in healthy adults and patients with asthma: Phase I first‐in‐human and first‐in‐patient trials

MP Kosloski, GD Kalliolias, CR Xu… - Clinical and …, 2022 - Wiley Online Library
Itepekimab is a monoclonal antibody that targets interleukin (IL‐33) and has been shown to
reduce airway inflammation and associated tissue damage in preclinical studies. We …

Native-like aggregates of factor VIII are immunogenic in von Willebrand factor deficient and hemophilia a mice

DS Pisal, MP Kosloski, CR Middaugh… - Journal of …, 2012 - Elsevier
The administration of recombinant factor VIII (FVIII) is the first-line therapy for hemophilia A (HA),
but 25%–35% of patients develop an inhibitory antibody response. In general, the …

Pharmacokinetics and tolerability of a dual variable domain immunoglobulin ABT‐981 against IL‐1α and IL‐1β in healthy subjects and patients with osteoarthritis of …

MP Kosloski, S Goss, SX Wang, J Liu… - The Journal of …, 2016 - Wiley Online Library
The interleukin (IL)‐1 family of proinflammatory cytokines are thought to play a significant
role in the structural progression of osteoarthritis and its associated symptoms. IL‐1α and IL‐1β …